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Glycogen synthase kinase-3 (GSK-3) is central to multiple intracellular pathways includ-
ing those activated by Wnt/β-catenin, Sonic Hedgehog, Notch, growth factor/RTK, and
G protein-coupled receptor signals. All of these signals importantly contribute to neural
development. Early attention on GSK-3 signaling in neural development centered on the
regulation of neuronal polarity using in vitro paradigms. However, recent creation of appro-
priate genetic models has demonstrated the importance of GSK-3 to multiple aspects
of neural development including neural progenitor self-renewal, neurogenesis, neuronal
migration, neural differentiation, and synaptic development.
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INTRODUCTION
Glycogen synthase kinase-3 (GSK-3), a serine–threonine kinase,
was originally identified as an important component of the glyco-
gen metabolism pathway. Later, however, it was found to be an
important regulator in multiple intracellular contexts. Recent
studies using pharmacological and genetic approaches have sug-
gested important functions for GSK-3 in an array of neural
developmental activities including neural progenitor homeosta-
sis, neuronal migration, neurite growth/specification, and synapse
development. Further, recent data indicate that the Disrupted in
Schizophrenia protein, DISC1, acts in part via GSK-3 suggesting
that dysregulated GSK-3 activity during development may con-
tribute to the pathogenesis of schizophrenia. Multiple proteins
that play important roles during neural development have been
identified as either GSK-3 substrates or binding partners (Table 1).
ISOFORMS OF GSK-3 IN THE NERVOUS SYSTEM
In mammals, the GSK-3 family consists of two members, GSK-
3α and GSK-3β that show 98% sequence identity within their
kinase domains and overall share 85% amino acid sequence iden-
tity (reviewed in Doble and Woodgett,2003). Both GSK-3 isoforms
are highly expressed in the nervous system including brain and
spinal cord. There are two splice variants of the GSK-3β and
one variant GSK-3β2 is highly expressed in the developing ner-
vous system (Mukai et al., 2002). It is interesting that GSK-3β2
is only expressed in differentiated neurons, not in glial cells while
GSK-3β1 is expressed in glial cells (Wood-Kaczmar et al., 2009).
Further, GSK-3β2 is upregulated in PC12 cells when induced by
nerve growth factor to differentiate into a neuronal phenotype
(Goold and Gordon-Weeks, 2001). These findings suggest that
differential regulation of GSK-3β isoform levels may be important
in the initiation of neuronal differentiation and the maintenance
of neurons during nervous system development.
Most functional studies of GSK-3 functions in mammalian
neural development have relied on pharmacological inhibitors in
dissociated preparations. However, since pharmacological GSK-3
inhibitors target ATP-binding pockets of both isoforms, distinc-
tive functional analysis of each isoform using pharmacological
inhibitors is not possible. Recently, studies in gene targeted mice
have begun to yield decisive information regarding the roles of
GSK-3 isoforms in neural development. Gene targeting of GSK-
3β leads to late embryonic lethality via liver apoptosis or heart
defects (Hoeflich et al., 2000; Kerkela et al., 2008). Surprisingly,
the developing nervous system of GSK-3β null mice including
the brain and spinal cord exhibits grossly normal morphology
(Kim et al., 2006). GSK-3β heterozygous (+/−) mice, however,
show multiple neurobehavioral abnormalities including aggressive
behaviors, increased anxiety, reduced movement, and poor mem-
ory processing (O’Brien et al., 2004; Beaulieu et al., 2008; Kimura
et al., 2008). Further, overexpression of GSK-3β in the brain results
in hyperactivity and mania (Prickaerts et al., 2006). Finally GSK-
3β is important in signaling downstream of dopamine receptors
(Beaulieu et al., 2004). These results demonstrate that the GSK-3β
isoform has important functions in regulation of behavior, prob-
ably via regulation of signaling downstream of neurotransmitter
receptors.
GSK-3α null mice are viable and fertile (MacAulay et al., 2007)
and show no abnormalities of gross anatomy in the developing
brain (Kim et al., 2009; Yokota et al., 2010). However, young
adult GSK-3α null mice show decreases in the size and num-
ber of cerebellar Purkinje cells and changes in social interaction
and locomotion (Kaidanovich-Beilin et al., 2009). GSK-3α dele-
tion also partially rescues the dendritic abnormality in cortical
neurons of DISC1-L100P mutant mice that show reduced spine
density compared to wild type mice (Lee et al., 2011). Further,
GSK-3α null mice are hypersensitive to insulin (MacAulay et al.,
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Table 1 | Glycogen synthase kinase-3-interacting proteins associated with neural development and diseases.
Name Neural development Diseases
Amyloid precursor protein Neurogenesis, neuron migration, synaptic development Alzheimer
APC Neurogenesis, neuron migration, neurite growth/polarization Autism, cancer
Axin Neurite growth/polarization Cancer
β-catenin Progenitor renewal, neurogenesis, neuron migration, neurite
growth/polarization, synaptic development
Cancer
CDK5 Neurogenesis, neuron migration, synaptic development Alzheimer, Parkinson, Huntington, ALS
c-Jun Progenitor apoptosis, neuron migration, neurite growth/polarization Cancer, Alzheimer, Parkinson
CLASP1, CLASP2 Neurite growth/polarization
c-Myb Progenitor renewal, neuronal apoptosis Cancer, liver disease
c-Myc Progenitor renewal, neurite growth/polarization Cancer, Alzheimer
CREB Progenitor renewal, neurogenesis, neuron migration, neurite
growth/polarization, synaptic development
Alzheimer, Huntington
CRMP2 Neurite growth/polarization Alzheimer
cyclin D1 Progenitor renewal, neurogenesis Cancer
δ-catenin Neurite growth/polarization, synaptic development Cri-du-Chat Syndrome
DISC1 Progenitor renewal, neuron migration, neurite growth/polarization
synaptic development
Schizophrenia, autism
Dvl Neurite growth/polarization Cancer
eIF2B Neurite growth/polarization Leukoencephalopathy
Kinesin light chain Progenitor renewal, neuron migration, neurite growth/polarization Alzheimer, ALS
LRP6 Dopaminergic neuron differentiation Heart disease
MAP1B Neurite growth/polarization Fragile X syndrome, giant axonal neuropathy,
Alzheimer, Parkinson
MAP2 Neurite growth/polarization Alzheimer
Myelin basic protein Myelination MS, seizure
NCAM Neuron migration, neurite growth/polarization Depression, Alzheimer, Parkinson
NeuroD Neurogenesis, neurite growth/polarization
Neurogenin2 Neurogenesis, neurite growth/polarization
NFAT Progenitor renewal, neurogenesis, neurite growth/polarization Cancer, Alzheimer, heart disease, kidney disease
Ninein Progenitor renewal, neurite growth/polarization
P53 Neurite growth/polarization, neuronal apoptosis Cancer
Presenilin 1 Neuron migration, neurite growth/polarization, synaptic development Alzheimer
PTEN Progenitor renewal, neurogenesis, neuron migration, neurite
growth/polarization, synaptic development
Autism, cancer, Cowden syndrome
SMAD1 Neurite growth/polarization
Tau Neurite growth/polarization Alzheimer
TSC2 Neuron migration, neurite growth/polarization Tuberous sclerosis, autism
2007), suggesting the potential roles of GSK-3α in hypothalamic
regulation. Using brain lysates of GSK-3α null, β null, and double
knockout mice, a recent study has demonstrated isoform-specific
activities on substrate phosphorylation in the brain. Each isoform
produces distinct phosphorylation patterns of CRMP2, CRMP4,
and Tau (Soutar et al., 2010). Together, these results indicate that
GSK-3α isoform has important specific functions in postnatal
neuroanatomy and behavioral regulation.
The lack of gross brain developmental abnormalities in GSK-3α
null and GSK-3β null mice suggests that either isoform might com-
pensate for the other in the regulation of differentiation, survival,
and morphogenesis of neurons and glia. Indeed, axon and den-
dritic morphogenesis is normal in cultured hippocampal neurons
from GSK-3β null embryonic brains (Kim et al., 2006). However,
genetic elimination of GSK-3 using an shRNA that targeted both
GSK-3 isoforms lead to strong changes in axon and dendritic mor-
phogenesis in cultured hippocampal neurons (Kim et al., 2006).
Further, the possibility of compensation has now been confirmed
in vivo. Conditional elimination of both GSK-3α and β at an early
stage (∼E10) of mouse nervous system development results in
dramatic effects on murine brain development (Kim et al., 2009).
REGULATION OF NEURAL PROGENITORS
There are several types of neural progenitors in rodent developing
brains (Figure 1). Radial neural progenitors are a major popu-
lation of neural progenitors and occupy the ventricular zone in
the developing brain. They display long radial processes to form a
scaffold covering from apical ventricular membrane to pial surface.
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FIGURE 1 | Neural progenitors in the developing brain. Radial glial
progenitors (RG) arise early in development from neuroepithelial cells. They
are located in the ventricular zone (VZ) and have long radial processes that
extend form VZ to the pial surface. A RG divides symmetrically to
self-renew and asymmetrically to generate a daughter RG and a
post-mitotic neuron or an intermediate progenitor (IP). IPs localize in the
subventricular zone (SVZ) and divide symmetrically to produce neurons.
There is another type of progenitors (oRG) in the superficial layer of SVZ or
in the intermediate zone (IZ). Like RGs, oRGs have glial processes and can
self-renew as well as generate neurons. For more information on oRG, see
a recent review by Kriegstein and colleagues (Lui et al., 2011). The role of
GSK-3 in regulating radial progenitors is now established. Functions related
to IPs and oRGs remain to be investigated.
This scaffold supports neuronal migration. Intermediate progen-
itors in the subventricular zone execute only the final neurogenic
division. In addition to radial and intermediate progenitors, there
are other types of neural progenitors more prominent in higher
species. Importantly, recent studies show existence of a greatly
expanded oRG (outer subventricular zone progenitors) in human
(Hansen et al., 2010) and mice (Wang et al., 2011). oRG progen-
itors are located in the outer region of the subventricular zone in
rodent. Unlike intermediate progenitors, this type of progenitor
can undergo self-renewal as well as symmetric neurogenesis.
EFFECTS OF GSK-3α AND β DELETION
Recent pharmacological evidence has strongly implicated GSK-
3 signaling in the regulation of embryonic stem cell self-renewal
(Sato et al., 2004; Umehara et al., 2007; Ying et al., 2008; Bone
et al., 2009). Further, DISC1 implicated in some familial cases of
schizophrenia and depression, regulates neural progenitor pro-
liferation and may act in part via regulation of GSK-3 activity
(Mao et al., 2009). These observations underscore the importance
of determining GSK-3 functions in relation to neural progenitor
self-renewal and neurogenesis during brain development in vivo.
The functions of GSK-3 in mammalian brain development
remained unclear because GSK-3 single isoform mutants had not
been associated with major brain developmental abnormalities
(see above). The results, however, did not exclude possible com-
pensatory effects of one GSK-3 isoform for the other in single null
mutant animals (Doble et al., 2007). To explore GSK-3 functions
definitively, a recent study pursued a conditional knockout strat-
egy in which a GSK-3β floxed allele was bred onto GSK-3α null
background to allow tissue specific elimination of GSK-3 signaling
(Kim et al., 2009). This study used a mouse strain expressing Cre
recombinase under the control of the neural specifying elements
of the nestin promoter (Tronche et al., 1999) to induce recombina-
tion around E10 in neuroepithelial cells as they convert to radial
progenitors and initiate neurogenesis (Yoon et al., 2008; Yokota
et al., 2009). The study conclusively demonstrated that elimina-
tion of both GSK-3 isoforms in the developing brain lead to a
massive increase in neural progenitor proliferation. This increase
was indicated by infolding of the developing cortical wall, major
increases in numbers of cells that expressed mitotic markers, and
a dramatic expansion of the population of neural progenitors
expressing Sox2. GSK-3 double knockout brains showed increased
progenitor division, premature re-entry and shortening of the cell
cycle.
Glycogen synthase kinase-3 deficient cells appeared to be locked
into the radial progenitor phase as generation of both intermedi-
ate neural progenitors and post-mitotic neurons was markedly
suppressed. In contrast to the expansion of Sox2-positive radial
progenitors, the population of intermediate neural progenitors
marked with Tbr2 was dramatically down-regulated in GSK-3
double knockout brains (Kim et al., 2009). Consistent with this
finding, only around one-third of the normal number of neu-
rons was generated in GSK-3 double knockout brains. Although
deletion of GSK-3 prevented progression of most cells beyond
the radial progenitor phase, a few progenitors were still capable
of differentiation as manifested by expression of Tbr2 and mark-
ers of post-mitotic neurons. Whether some progenitors can truly
progressed independently of GSK-3 signaling or whether the dif-
ferentiated cells represented a population of radial progenitors
that had some persistent GSK-3 proteins due to either late or
incomplete deletion of GSK-3 remained unclear.
MECHANISMS ASSOCIATED WITH GSK-3 REGULATION OF NEURAL
PROGENITORS
Multiple extracellular signals and intracellular signaling mecha-
nisms that regulate neural progenitor proliferation and differen-
tiation have been identified (reviewed in Corbin et al., 2008).
The mechanisms that have received the most attention in the
dorsal telencephalon are β-catenin/LEF1 and Notch signaling
(Figure 2A). Whether these mechanisms operate independently
or are coordinately regulated is an interesting question. GSK-3
has the potential to influence both mechanisms. It is important
to emphasize that GSK-3s are also key components in pathways
downstream of two extracellular signals, FGF2 and Shh, which also
strongly regulate progenitor proliferation in the developing telen-
cephalon (Figure 2A; Vaccarino et al., 1999; Raballo et al., 2000;
Komada et al., 2008; Shimizu et al., 2008).
β-Catenin signaling and GSK-3
It is well known that regulation of β-catenin is critical to control
of progenitor proliferation in multiple regions of the developing
nervous system (Chenn and Walsh, 2002; Machon et al., 2003,
2007; Zechner et al., 2003; Woodhead et al., 2006; Gulacsi and
Anderson, 2008). As expected, β-catenin was increased substan-
tially in GSK-3 double knockout brains, consistent with the critical
importance of GSK-3 in phosphorylating β-catenin in the destruc-
tion complex that mediates canonical Wnt signaling (Kim et al.,
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FIGURE 2 | Glycogen synthase kinase-3 is a key regulator of multiple
signaling pathways in neural progenitors. (A) GSK-3 controls gene
induction by regulating the levels of transcription factors in neural
progenitors. β-catenin is degraded via GSK-3 phosphorylation-dependent
ubiquitin-protease machinery in the resting state. However, inhibition of
GSK-3 by Wnt allows β-catenin accumulation. GSK-3 is also critical in the
control of c-Myc levels. c-Myc is phosphorylated at T58 and recruited by
ubiquitin-protease for degradation. FGF inhibits GSK-3 via AKT-mediated
phosphorylation at S9 (beta) or S21 (alpha) and leads to increase in c-Myc
levels. Inhibition of GSK-3 increases Notch intracellular domain (NICD) and
Gli proteins in neural progenitors. Thus, GSK-3 activity is critical in the
control of transcription factors in multiple signal pathways, which eventually
regulates neural progenitors during development. (B) A schematic model of
the GSK-3 function in apical–basal polarity and neurogenesis. GSK-3 is
required for polarity establishment and possibly for neurogenic division of
progenitors. Polarity-associated molecules including β-catenin, atypical
PKC, APC, and cadherin are localized in the apical membrane. When
progenitors divide, daughter cells that inherit the polarity molecules are
thought to become progenitors. Without the polarity protein, cells become
neurons. However, in GSK-3-deleted neural progenitors, polarity molecules
are distributed throughout the cell. Thus, wherever the cleavage plane is
positioned, daughter cells have almost same composition of the molecules.
This may be an important factor that leads constant self-renewal of
progenitors in GSK-3-deleted brains.
2009). However, stabilization of β-catenin alone may not have
fully accounted for the effects of progenitor hyperproliferation in
GSK-3 double knockout brains. Although it is difficult to compare
studies directly, it appears that the enlarged brain observed upon
overexpression of a stabilized β-catenin is associated with a more
normal pattern of neuronal differentiation than GSK-3 double
knockout brains (Chenn and Walsh, 2002, 2003; Kim et al., 2009).
Further, elimination of β-catenin in neural progenitors reduces but
does not eliminate progenitor proliferation in vivo (Machon et al.,
2003; Zechner et al., 2003; Gulacsi and Anderson, 2008). Finally,
overexpression of dominant-negative TCF only partially inhibited
proliferation in GSK-3 knockout neural progenitors in vitro (Kim
et al., 2009). Thus, GSK-3 may regulate self-renewal of neural
progenitors by mechanisms in addition to β-catenin signaling.
Notch signaling and GSK-3
Notch signaling is critical to the maintenance and the identity of
radial glial cells during development (Gaiano et al., 2000; reviewed
in Ohtsuka et al., 2001; Hatakeyama et al., 2004; Yoon and Gaiano,
2005; Mizutani et al., 2007; Shimojo et al., 2008). There are several
mechanisms by which GSK-3 may regulate Notch signaling both
directly and indirectly (Foltz et al., 2002; Espinosa et al., 2003;
Uemura et al., 2007; Hayward et al., 2008; Shimizu et al., 2008;
Jin et al., 2009a). For example, GSK-3β is able to bind and phos-
phorylate Notch2 in vitro and in vivo (Espinosa et al., 2003). The
GSK-3α isoform likely has the same function, because the phos-
phorylation was inhibited by the treatment of Wnt (Espinosa et al.,
2003). Thereby, GSK-3 inhibits the transcriptional activation of
Notch target genes. Also, β-catenin reportedly enhances the level
and transcription activity of Notch1 (Shimizu et al., 2008; Jin et al.,
2009b). Meanwhile, there are conflicting studies with regard to the
role of GSK-3 in Notch signaling, in which inhibition of GSK-3
using pharmacological drugs or genetic tools decreased NICD lev-
els in neuroblastoma cells (Foltz et al., 2002) and vascular smooth
muscle cells (Guha et al., 2011).
Notch signaling was shown to be increased in GSK-3 double
knockout brains (Kim et al., 2009). Levels of Notch intracellular
domain were markedly enhanced as were levels of the Notch down-
stream signaling mediators Hes1 and Hes5. Further, immunohis-
tochemical data suggested that most or all of the extra progenitors
in GSK-3 double knockout mice express high levels of Hes1 pro-
tein, indicative of active Notch signaling in these cells. Levels of
Jagged-1, a Notch agonist, were increased in GSK-3-deleted brain
lysates, suggesting that the activation of Notch pathway upon
GSK-3-deletion requires a Notch agonist. This is different from
the activation of β-catenin signal, which is induced in GSK-3-
deleted cells in the absence of Wnt ligands (Doble et al., 2007).
Overexpression of a dominant-negative Hes1 and pharmacologi-
cal inhibition of Notch signaling partially inhibited proliferation in
GSK-3-deleted progenitors (Kim et al., 2009). Interestingly, Notch
signaling levels distinguish radial progenitors from intermediate
neural progenitors that have attenuated canonical Notch signaling
(Mizutani et al., 2007). Therefore, high levels of Notch signaling in
GSK-3 double knockout cells may have suppressed neurogenesis
at the stage of radial progenitors such that few cells progress to the
stage of Tbr2-positive intermediate neural progenitors. However,
whether GSK-3 regulated Notch signaling directly or indirectly
via regulation of β-catenin or some other mechanism was not
established.
GSK-3 regulation of Myc
GSK-3 is a downstream mediator of FGF/PI3K signaling in neural
progenitors (Shimizu et al., 2008). Several recent studies have
demonstrated that GSK-3 regulates the stability of Myc family pro-
teins via the PI3K pathway (reviewed in Knoepfler and Kenney,
2006; Bechard and Dalton, 2009; reviewed in Doble and Wood-
gett, 2009; Otto et al., 2009). It is important to emphasize that
GSK-3 can directly regulate the stability of Myc family proteins,
independently of β-catenin effects on Myc transcription (Bechard
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and Dalton, 2009; reviewed in Doble and Woodgett, 2009; Otto
et al., 2009). Interestingly, these effects are thought to be down-
stream of RTK/PI3K rather than Wnt/Frizzled signaling (reviewed
in Knoepfler and Kenney, 2006). Myc family proteins are key ele-
ments in the maintenance of neural progenitors by inhibiting
differentiation (Knoepfler et al., 2002; Wey et al., 2010). Phos-
phorylation of c-Myc at T58 thought to be a key to its stability
is regulated by GSK-3. The GSK-3-mediated phosphorylation at
T58 plays an important role in inducing cell differentiation, as
inhibition of the phosphorylation maintains embryonic stem cell
pluripotency (Cartwright et al., 2005). This phosphorylation was
shown to be eliminated in GSK-3 double knockout brains and the
level of c-Myc was increased (Kim et al., 2009). Given the short
half-life cycle of c-Myc (∼20 min; reviewed in Eilers and Eisen-
man, 2008), control of c-Myc stability via T58 phosphorylation
may be a critical step in GSK-3 regulation of neural progenitor
self-renewal.
Myc binds to promoters of many genes including cyclins and
regulates their transcription. This traditional role as a transcrip-
tion factor has been primarily considered in maintaining self-
renewal and in inhibiting differentiation of stem cells. But several
recent reports suggest that Myc contributes to stem cell mainte-
nance in other ways by globally maintaining the histone acetylation
and methylation euchromatin state (Lin et al., 2009; reviewed in
Varlakhanova and Knoepfler, 2009; Araki et al., 2011). Whether
Myc elicits changes in histone methylation patterns of promot-
ers in neural progenitors and whether GSK-3 is associated with
this process remain to be elucidated. Further characterization of
functional genomic analysis will likely elucidate Myc functions as
epigenetic transcriptional regulator in neural progenitors.
Apical–basal polarity and GSK-3
Cell polarity is a fundamental property of all cells including
neural progenitors. GSK-3 is thought to be a key regulator of
cell polarity and microtubule-cytoskeleton regulation based on
in vitro studies (Etienne-Manneville and Hall, 2003; reviewed in
Buttrick and Wakefield, 2008). GSK-3 directly binds to polarity-
associated proteins including APC (Adenomatous polyposis coli),
EB1 (End binding 1), and CLASPs (Cytoplasmic linker-associated
proteins) and regulates their activities by phosphorylation. For
example, APC and CLASPs promote microtubule stability and
their phosphorylation by GSK-3 inhibits microtubule binding,
thus destabilizing microtubules (Akhmanova et al., 2001; Zum-
brunn et al., 2001). Asymmetric cell division results from polarized
deposition of polarity proteins and it is required for neurogenic
division of radial neural progenitors (Gotz and Huttner, 2005).
Apical–basal polarity indicated by the distribution patterns of
cell polarity/adhesion proteins including APC, EB1, cadherin, and
aPKC was disrupted in GSK-3-deleted developing brains (Kim
et al., 2009). Thus, the expansion of the radial progenitor pool
and inhibition of neurogenesis in GSK-3-deficient brains may
be attributed in part to the dysregulation of polarity-associated
proteins (Figure 2B). Localized distribution patterns of apical
molecules may be coordinated by GSK-3 regulation of the micro-
tubule apparatus or motor proteins. In this regard, it is notable
that elimination of polarity-associated molecules, Lgl1 and αE-
catenin results in a major hyperproliferation of neural progenitors
(Klezovitch et al., 2004; Lien et al., 2006).
It has also been demonstrated that GSK-3 regulates centrosome
reorientation and microtubule spindle formation during cell divi-
sion (Wakefield et al., 2003; Cheng et al., 2008; Izumi et al., 2008).
Dysregulation of centrosome positioning and cleavage planes may
favor divisions that result in additional progenitors rather than
post-mitotic neurons (reviewed in Higginbotham and Gleeson,
2007). An important implication of these findings is that apical–
basal polarity and centrosome positioning may be among of the
mechanisms responsible for GSK-3-mediated neural progenitor
homeostasis.
DISC1 and GSK-3 signaling
A recent study has shown that GSK-3 binds to DISC1 and that
pharmacological inhibition of GSK-3 can mitigate effects of DISC1
shRNA knockdown on neural progenitor proliferation in vitro
(Mao et al., 2009). DISC1 protein does not have enzymatic activ-
ity, rather it functions as a physiological scaffold by interacting
with multiple proteins to modulate their functional activities.
For example, DISC1 binds to NUDEL (Duan et al., 2007) and
girdin (Enomoto et al., 2009), and modulates the activities of these
proteins in adult neural progenitors and their progeny. Likewise,
DISC1 may serve as an important scaffold to bridge GSK-3 and its
regulators in neural progenitors during development.
HOMEOSTATIC CONTROLS IN NEURAL PROGENITORS
During nervous system development, an over-abundance of cells is
produced presumably to accommodate the significant loss of cells
that fail to achieve functionality. This overproduction allows for
remarkable plasticity in nervous system development but requires
exquisite inductive coordination. Temporal and spatial regulation
of GSK-3 activity during nervous system development must be
achieved in order to terminate neural progenitor proliferation and
allow differentiation at just the right moment to yield the correct
number of neurons. It is remarkable that regulation of the activity
of a single kinase provides a powerful and simple mechanism to
control neural progenitor homeostasis.
The functions of GSK-3 in radial neural progenitors have
been discussed above. However, whether GSK-3 has significant
roles in intermediate progenitors and oRGs remains to be eluci-
dated. It will be important to see if GSK-3-deletion also results in
self-renewal of these progenitors.
GSK-3 SIGNALING IN NEURONAL MIGRATION
After progenitor proliferation and neurogenesis, post-mitotic neu-
rons migrate to final locations which in the cortex results in
proper lamination. There is increasing evidence that GSK-3 may
be important in regulating neuronal migration.
Wnt SIGNAL AND NEURON MIGRATION IN C. ELEGANS
Recent studies have shown that Wnt family molecules play impor-
tant roles in controlling anterior/posterior (AP)-directed neuronal
cell migration and polarity in C. elegans (reviewed in Silhankova
and Korswagen, 2007). Multiple Wnt proteins function in paral-
lel as instructive cues or permissive signals to control neuronal
migration along the AP axis. EGL-20/Wnt is one of the five Wnt
proteins of C. elegans and specifies posterior direction of Q neu-
roblast migration (Harris et al., 1996; Maloof et al., 1999). This
protein activates a canonical Wnt pathway (β-catenin-dependent)
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in the Q neuroblast (Salser and Kenyon, 1992; reviewed in Korswa-
gen, 2002). Accordingly, overexpression of SGG-1, the C. elegans
GSK-3β ortholog induced defects in Q cell migration far toward
anterior region (Korswagen et al., 2002). Together, these suggest
that GSK-3 signaling plays an important role in C. elegans neuron
migration by negatively regulating Wnt signaling.
Wnt SIGNALING MOLECULES AND NEURONAL MIGRATION IN MICE
Considerable evidence both direct and indirect now implicates
GSK-3 in regulation of neuronal migration in mice. Some evi-
dence has come from functional studies of the GSK-3 target and
destruction complex component,APC. In addition to its role in the
destruction complex, APC is a microtubule-associated protein and
participates in microtubule-based cytoskeleton dynamics (Barth
et al., 2008). GSK-3 directly binds to APC and phosphorylates it in
order to regulate its activity. APC phosphorylation by GSK-3 dis-
sociates APC from microtubules. A recent study has demonstrated
that APC serves an essential function in the maintenance of the
polarized radial glial scaffold during mouse brain development
(Yokota et al., 2009). Elimination of APC in radial progenitors
by conditional gene targeting lead to striking defects in cortical
lamination, suggesting an important role for APC in neuronal
migration. However, it is not clear whether migration defects were
entirely due to disruption of the radial glia scaffold or whether
APC regulation of microtubules in neurons also contributed. It
will be important to settles this issue with conditional elimination
of APC specifically in early post-mitotic cortical neurons.
GSK-3 may also affect neuronal migration via regulation of
β-catenin. Several studies have shown that genetic manipulation
of β-catenin by either deletion or overexpression of a stabi-
lized form in mice leads to the disruption of brain and spinal
cord formation (Chenn and Walsh, 2002, 2003; Zechner et al.,
2003). The malformation is mostly attributed to abnormal neural
progenitor development. However, there were also abnormally
localized neurons found in the mutant nervous system. Fur-
ther, a separate study has demonstrated that β-catenin levels
in progenitors influenced cortical neuron positioning (Mutch
et al., 2009). A caveat of this interpretation is that the abnor-
mal neuronal positioning may be due to a delay in progeni-
tor fate determination. However, the β-catenin mutation stud-
ies again strongly suggest potential roles for GSK-3 in neuronal
migration.
DISC1 regulates neuronal migration during brain development
(Kamiya et al., 2005) and is strongly associated with GSK-3. DISC1
binds to GSK-3 and the interaction interferes with GSK-3 inhi-
bition of the β-catenin signal in neural progenitors, resulting in
progenitor proliferation (Mao et al., 2009). Recently, the interac-
tion between DISC1 and GSK-3 has been implicated in control of
cortical neuronal migration (Ishizuka et al., 2011). DISC1 bound
to GSK-3 tightly during mid-embryonic stage (E14) in which
neural progenitor proliferation is active (Figure 3A). But, DISC1
was dissociated with GSK-3 during later embryonic stages (E18)
when neuronal migration and neuronal differentiation become
dominant. These findings suggest that the DISC1/GSK-3 inter-
action determines transition of neural progenitor self-renewal to
neuronal migration in the developing brain.
Additional relevant evidence about the role of GSK-3 in neu-
ron migration has been recently reported. Radial migration and
FIGURE 3 | Glycogen synthase kinase-3 in neuronal migration. (A)
GSK-3 is required for neuronal migration. During early stages of
development, DISC1 that is an important regulator of neuron migration
binds to GSK-3, resulting in dissociation of GSK-3 from β-catenin. The
increased β-catenin level directs progenitors to self-renew. However, the
binding activity of DISC1 decreases at later stages of embryogenesis,
which induces reduction in β-catenin level via GSK-3 phosphorylation.
Progenitors then produce more neurons that subsequently migrate from
the ventricular zone (Ishizuka et al., 2011). (B) Microtubules are stabilized
at the leading edge of migrating neurons by GSK-3 inactivation. LKB1
inactivates GSK-3 by the phosphorylation at S9. APC is dissociated from
GSK-3 and binds to microtubules at the leading edge of migrating
neurons (Asada and Sanada, 2010), which stabilizes microtubules
(glu-tubulin).
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placement of cortical neurons were aberrant in GSK-3/nestin-cre
mutant mice (Yokota et al., 2010). This study showed that, com-
pared to control brains, fewer deeper layer neurons (Tbr1-positive)
were found in the cortical plate of GSK-3 double knockout brains.
Substantial numbers of Tbr1 neurons were trapped within the
intermediate zone. Yet, GSK-3/nestin-cre mutant brains also show
disrupted radial glial development (Yokota et al., 2010). The dis-
ruption of radial glial platform may indirectly create radial neuron
migration defects in GSK-3/nestin-cre brains. Therefore, elimi-
nation of GSK-3 only in neuronal population needs to be done
to establish whether or not GSK-3 has a direct role in neuronal
migration in developing mammalian brains.
A separate study has recently shown that in utero electro-
poration with active GSK-3β plasmid into cortical ventricular
zone elicits neuronal migration defects (Asada and Sanada, 2010).
LKB1 that is an important regulator of neuronal migration in the
developing cortex (Asada et al., 2007) mediated GSK-3β phospho-
rylation at Serine 9 residue. The phosphorylation induced high
levels of APC and Glu-tubulin (stabilized microtubule) at the
leading process of neurons, thereby directing centrosomal move-
ment. However, inhibition of the Serine 9 phosphorylation by
overexpressing active GSK-3β (S9A) resulted in very low levels of
APC and Glu-tubulin at the leading process of migrating neu-
rons. These results suggest that GSK-3 inactivation via Serine 9
phosphorylation is required for directional migration of cortical
neurons by rearranging APC and stabilizing microtubules at the
leading process (Figure 3B). An important point of this study is
that only sub-population of cortical ventricular cells are manipu-
lated by the gene transfection, leaving surrounding environment
including radial glial platform mostly intact.
Although this initial work outlined above has provided valu-
able information on GSK-3 functions in neuronal migration, it is
important now to define the molecular and cellular mechanisms
of GSK-3 regulation. For example, GSK-3 may regulate neuronal
migration during development by directing gene transcription
and/or by rearranging the intracellular cytoskeleton. Results from
β-catenin and active GSK-3 overexpression studies strongly sug-
gest that both mechanisms may be significant to GSK-3 regulation
in neuronal migration. Defining GSK-3 functions and associated
mechanisms has important clinical implications since defects in
neuron migration are implicated in a range of neurodevelopmen-
tal disorders. Mutations in DISC1 are causative in some cases of
schizophrenia.
NEURONAL MORPHOGENESIS
After migration, GSK-3 is critically involved in neuronal
morphological development including neurite outgrowth and
axon/dendritic specification. The roles of GSK-3 on axon/dendrite
development are described well in the article in the same issue from
Zhou and Snider.
GLIAL DEVELOPMENT
Although not yet tested, it can be anticipated that GSK-3 will
also have important functions related to glial development. IGF1
and FGF2 pathways coordinately control the cell cycle progres-
sion of oligodendrocyte progenitors via cyclin D1 expression and
localization (Frederick and Wood, 2004). The turnover of this
protein is regulated by GSK-3-dependent proteasome degrada-
tion (Diehl et al., 1998). GSK-3β is phosphorylated in the presence
of IGF1 downstream of PI3K/AKT signaling in oligodendrocyte
progenitors (Frederick et al., 2007). This suggests that GSK-3 activ-
ity is inhibited by IGF1 in oligodendrocyte progenitors, which then
enhances the stability and nuclear localization of cyclin D1 protein.
Furthermore, inhibition of GSK-3 in postnatal mice by injecting
pharmacological inhibitors increased oligodendrocyte differenti-
ation and myelination (Azim and Butt, 2011). This effect was
via canonical Wnt signaling stimulating β-catenin. Thus, these
findings suggest that GSK-3 may be a crucial to oligodendrocyte
differentiation.
Activation of PI3K and inhibition of GSK-3 using lithium pro-
mote Schwann cell differentiation (Ogata et al., 2004). This finding
suggests that GSK-3 as a downstream of PI3K–AKT pathway is
crucial for initiation of myelination during development. It will
be important in future work to define aspects of GSK-3 signaling in
gliogenesis during neural development that might have additional
implications in the context of glial tumors and demyelinating
diseases.
SYNAPTIC DEVELOPMENT
Synapses connect neurons to transmit signals and synapse forma-
tion is an important step in later stages of development. Recent
studies have suggested important functions for GSK-3 in synap-
tic development. Shaggy, the fly homolog of GSK-3, is present
at synapses and negatively influences AP-1-dependent synaptic
growth, by modulating the Jun-N-terminal kinase pathway, and
regulates presynaptic neurotransmitter release at the larval neu-
romuscular junction (Franciscovich et al., 2008). In fractionation
studies, GSK-3β is readily detected within the synaptosomal frac-
tion (Hooper et al., 2007). Activation of GSK-3 by transfecting
GSK-3 genes in cultured neurons reduces expression and cluster-
ing of a synaptic protein Synapsin I (Zhu et al., 2007). In contrast,
pharmacological inhibition of GSK-3 activity induces Synapsin I
clustering in developing neurons (Hall et al., 2002). Further, GSK-3
activation reduces presynaptic glutamate release by inhibiting the
synaptic vesicle exocytosis in response to membrane depolariza-
tion (Zhu et al., 2010). GSK-3β negatively regulates synaptic vesicle
fusion events via interfering with Ca2+-dependent SNARE com-
plex formation. Finally, in rat, there is strong GSK-3 expression in
dendritic spines of cultured hippocampal neurons (Peineau et al.,
2007).
Glycogen synthase kinase-3 activity is also implicated in regu-
lation of adult synapses. GSK-3 plays a role in amyloid-induced
synaptic alternation and dendritic spine shortening (reviewed in
Knobloch and Mansuy, 2008). All these demonstrate that GSK-3
signaling is likely critical to synaptic development, but the precise
functions regulated by GSK-3 will require further study.
A recent study has reported functional roles of GSK-3 in
the regulation of N -Methyl-d-aspartic acid (NMDA) receptor-
dependent synaptic plasticity (Peineau et al., 2008). Activation of
GSK-3 mediates NMDA-dependent long term depression (LTD)
induction. In contrast, inhibition of GSK-3 activity prevents
LTD induction and participates in long term potentiation (LTP)
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induction (Hooper et al., 2007). For further information on the
roles of GSK-3 in synaptic plasticity and LTP/LTD formation,
please refer the review from Collingridge group in this issue.
GSK-3 IN TUMORIGENESIS
DUAL FUNCTIONS OF GSK-3 IN TUMORIGENESIS
Glycogen synthase kinase-3 is associated with neoplastic trans-
formation and tumor development (reviewed in Ougolkov and
Billadeau, 2006; reviewed in Luo, 2009). Since GSK-3 negatively
regulates oncoproteins such as Myc and β-catenin, it may act as a
suppressor of tumorigenesis. Indeed, downregulation of GSK-3β
and upregulation of phospho-GSK-3β (inactive form) have been
found in skin (Leis et al., 2002; Ding et al., 2007; Ma et al., 2007)
and mammary tumors (Farago et al., 2005) in mice and humans.
Furthermore, overexpression of wild type or constitutively active
GSK-3β inhibits the progression of skin tumors in mice (Ma
et al., 2007), while mice overexpressing dominant-negative GSK-3
develop mammary tumors (Farago et al., 2005). The promotion of
mammary tumorigenesis by GSK-3 inactivation is accompanied
by the accumulation of β-catenin and cyclin D1, suggesting the
dysregulation of the Wnt pathway. These findings demonstrate the
suppressive role of GSK-3 in tumorigenesis. However, some stud-
ies have shown the contrary role of GSK-3, that it may positively
regulate tumorigenesis in other types of cancers. Increased GSK-
3 levels have been found in human ovarian, colon, liver, thyroid,
and pancreatic carcinomas (reviewed in Ougolkov and Billadeau,
2006; reviewed in Luo, 2009). Inhibition of GSK-3 activity by
pharmacological inhibitors or RNA interference suppresses pro-
liferation of the human ovarian cancer (Cao et al., 2006), colon
cancer (Shakoori et al., 2007), pancreatic cancer (Ougolkov et al.,
2005), and prostate cancer cells (Zhu et al., 2011). Conversely,
overexpressing constitutively active GSK-3β induces cell cycle pro-
gression of ovarian cancer cells (Cao et al., 2006). Therefore,GSK-3
also functions as a tumor promoter in certain types of tumors. In
this case, inhibition of GSK-3 could be an attractive therapeu-
tic strategy for the treatment of ovarian, colon, and pancreatic
cancers. Taken together, GSK-3 plays opposing roles as a tumor
suppressor or a promoter, depending on cell-types and cellular
contexts.
TUMORIGENESIS IN THE NERVOUS SYSTEM
Recent studies suggest important roles of GSK-3 in the formation
and maintenance of tumors in the nervous system. Pharmaco-
logical inhibition of GSK-3 using the indirubin family reduces
growth and invasion of human glioma cells both in vitro and in
mice (Nowicki et al., 2008; Williams et al., 2011). β-catenin sig-
naling plays an important role in mediating these effects. Another
study using a different GSK-3 inhibitor, TDZD-8, has also shown
that inhibition of GSK-3 activity suppresses proliferation of mouse
glioma cells and induces apoptosis in vitro (Aguilar-Morante et al.,
2010). The inhibitory effects of TDZD-8 in culture were con-
firmed in mice, which showed delay in tumor growth after glioma
cell injection, and an increase in survival (Aguilar-Morante et al.,
2010). Additionally, GSK-3 is involved in the differentiation of
human glioma cells (Korur et al., 2009). Interference of GSK-3
activity with siRNA or pharmacological inhibitors induces dif-
ferentiation of glioma cells. The capacity of GSK-3 in inducing
glioma cell differentiation could be considered for the differen-
tiation therapy that has emerged as a promising treatment tool
for brain tumors. However, progression of this idea needs careful
assessments, as contrary effects of GSK-3 on glioma differentiation
are also reported (Li et al., 2010). GSK-3 also plays a promoting
role in the majority of medulloblastoma, the most common pedi-
atric malignant tumor of the central nervous system. Lithium,
a clinically available GSK-3 inhibitor, suppresses proliferation
of medulloblastoma cells and induces non-apoptotic cell death
(Ronchi et al., 2010). Interestingly, the inhibitory effect of GSK-
3 is independent of changes in intracellular levels of β-catenin.
Together, GSK-3 signaling plays important roles in tumorigenesis
and differentiation in the nervous system, and may be a promis-
ing target in the establishment of therapeutic strategies. However,
before considering clinical application, it is necessary to deter-
mine the suppressive and promoting functions of GSK-3 in each
tumor type, as both activities have been evident in non-nervous
system tumors. This dual role of GSK-3 in tumorigenesis may
not be surprising since GSK-3 is involved in multiple pathways
and regulates many substrates. Different environments and/or
epigenetic programs around different tissues/cells may regulate
GSK-3 in different ways, which subsequently influences distinct
downstream targets. In this regard, it is important to define
and compare GSK-3 signaling mechanisms in each cell-type.
This will delineate how the suppressive and promoting activities
of GSK-3 are counterbalanced and help to develop therapeutic
potentials.
IMPLICATIONS IN NEURODEVELOPMENTAL DISORDERS
Recent studies suggest that changes in GSK-3 activity may be
an important aspect of pathophysiologies of neurodevelopmental
disorders, including autism spectrum disorders (ASDs), schizo-
phrenia, mental retardation, and bipolar disorders. There are two
types of key observations in animal models of neurodevelopmen-
tal disorders: (1) The levels and activity of GSK-3 are altered in the
brain samples. (2) Pharmacological or genetic inhibition of GSK-3
activity reduces the pathological symptoms. In humans, lithium,
a GSK-3 inhibitor is used for controlling abnormal mood changes
in patients with bipolar disorders.
ASDs are a spectrum of psychological conditions character-
ized by abnormalities in social interactions and communication
as well as stereotypic behaviors and motor dysfunctions. Neu-
rodevelopmental abnormalities are found in ASD brains. Studies
using magnetic resonance imaging and postmortem brains show
abnormalities in cortical minicolumn organization and neuron
migration in patients with ASDs (Piven et al., 1990; Casanova et al.,
2003, 2006). Etiology of autism has yet to be determined. However,
recent studies suggest that genetic factors may be the most signifi-
cant cause for ASDs. Gene linkage studies and array analyses have
found multiple ASD-associated genes that encode FMR1 (fragile X
mental retardation 1), PTEN (phosphatase and tensin homolog),
APC, DISC1, SHANK3 (SH3 and multiple ankyrin repeat domains
3), TSC (tuberous sclerosis), MeCP2 (methyl CpG binding protein
2), and Reelin (reviewed in Abrahams and Geschwind, 2008). All
these genes play important roles in functional and anatomical
development of the nervous system.
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Importantly, GSK-3, a critical regulator in broad aspects of
neural development, is associated with many ASD-related genes
mentioned above. GSK-3 activity measured by the levels of
phospho-GSK-3 is increased in the brains of FMR1-deleted mice
(Min et al., 2009; Yuskaitis et al., 2010). Inhibition of GSK-3 activ-
ity by treatment with lithium reduces abnormal social behaviors
and seizures in the FMR1 mice. Additionally, GSK-3 knock-in
mice, in which inhibitory serine 9 (β) and 21 (α) residues are sub-
stituted by alanine (McManus et al., 2005), show abnormal social
behaviors similar to those of FMR1-deleted mice (Mines et al.,
2010). Mice with conditional PTEN deletion in the cortex and
hippocampus show macrocephaly and abnormal social interaction
(Kwon et al., 2006). The levels of inactive GSK-3β (phospho-GSK-
3β) are elevated in the brains. Furthermore, recent studies suggest
that GSK-3 is a critical downstream mediator of the DISC1 signal.
DISC1 regulates proliferation of neural progenitors by modulat-
ing GSK-3 activity (Mao et al., 2009). DISC1 directly binds to
GSK-3 and participates in the regulation of β-catenin stability.
Inhibition of GSK-3 with lithium or overexpression of a stable
β-catenin rescues DISC1-deletion effects in neural progenitors.
However, whether DISC1 directly controls GSK-3/β-catenin or
serves as a scaffold remains unknown. Together, GSK-3 is associ-
ated with genes that are mutated in neurodevelopmental disorders
and may play a critical role in the pathogenesis of the diseases. The
association of GSK-3 with these genes suggests a therapeutic inter-
vention point in the development of tools for neurodevelopmental
disorders.
GSK-3 IN EPIGENETIC CONTROL
Epigenetic control has become an important cell-intrinsic pro-
gram in the regulation of various processes during neural develop-
ment. DNA methylation and histone modification (i.e., phospho-
rylation, acetylation, and methylation) change chromatin struc-
tures for transcription factors to gain access to gene promoters
(Fischle et al., 2003). Non-coding RNAs also functionally par-
ticipate in neural development. For example, microRNAs regu-
late neural progenitor proliferation and differentiation (Aranha
et al., 2011; Chen et al., 2011), neural migration (Delaloy et al.,
2010), oligodendrocyte differentiation and myelination (Dugas
et al., 2010), hippocampal axon growth (Sanuki et al., 2011), and
dendritic spine morphogenesis (Lippi et al., 2011).
The role of GSK-3 in epigenetic control has recently been evi-
dent. GSK-3 modulates the activity of epigenetic factors. GSK-3
directly phosphorylates histone deacetylase 3 that promotes the
death of cortical neurons (Bardai and D’Mello, 2011), suggest-
ing that the neuronal death-promoting activity of GSK-3 could
be mediated via an epigenetic mechanism. Pharmacological inhi-
bition of GSK-3 increases methylation at several sites on histone
H3 and histone H4 bound to the promoters of the NFκB target
genes Bcl-2 and XIAP (Ougolkov et al., 2007). This leads to the
suppression of NFkB binding to its target promoters and thereby
epigenetic silencing of XIAP and Bcl-2. Additionally, a recent study
demonstrates that GSK-3 also participates in epigenetic control
by regulating the levels of a DNA methyltransferase. Genetic dele-
tion of both GSK-3α and GSK-3β in mouse embryonic stem cells
reduces expression of DNA methyltransferase 3a2, which results in
hypomethylation and misexpression of the imprinted genes Igf2,
H19, and Igf2r (Popkie et al., 2010). Our understanding of this
subject is at an initial stage, but the information thus far strongly
suggests important roles of GSK-3 in epigenetic control. This field
will be expanded by identifying more epigenetic molecules that
are regulated by GSK-3.
CONCLUSION
All of the studies discussed here implicate GSK-3 as a multifunc-
tional regulator of neural development. At early stages, GSK-3
serves as a master switch regulating neural progenitor home-
ostasis and appears to act via regulation of β-catenin as well as
other key signaling pathways. It now seems quite clear that after
progenitors differentiate into neurons, GSK-3 signaling is also key
to neuronal migration and lamination. Although some evidence
implicates β-catenin in these processes, GSK-3 regulation of the
cytoskeleton via APC and other microtubule-associated proteins
may be particularly important. Finally, functions of GSK-3 in neu-
ronal morphogenesis, synaptogenesis, and behavior are only now
being defined. Future studies defining cell-type specific effects
in vivo with a variety of Cre drivers will rapidly enhance our
understanding of GSK-3 functions.
A key regulator of GSK-3 function in neural development is an
important protein in genetic causes of schizophrenia. Details of
GSK-3 regulation by DISC1 have already provided key insights
into regulation of key developmental events with important
implications to the pathogenesis of some cases of schizophrenia.
Finally, our current understanding of GSK-3 in neural develop-
ment largely reflects phenotypic characterization of the loss of the
protein. It will be important to learn more cellular and molecular
mechanisms of GSK-3 signaling related to these striking pheno-
types. Further works should distinguish GSK-3 functions between
gene induction activity and cytoskeleton regulation and how these
processes are linked in various neurodevelopmental events. Also,
key to defining GSK-3 functions will be to understand how GSK-3
activity is regulated. Understanding regulation of GSK-3 activity
will be a particularly important goal, as we can expect that even
relative small changes might have a large impact on important
developmental outcomes such as determination of numbers of
neurons in the brain.
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